Breathe Well Live Well
|
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in …
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with … |
View full post on asthma – Google News
|
Dual-action Sanofi asthma drug performs well in test
Allentown Morning Call Nov 11 (Reuters) – An experimental biotech drug for severe asthma from France's Sanofi, which has a location in Swiftwater, Monroe County, and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism … |
View full post on asthma – Google News
Reuters |
Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII
FierceBiotech Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development … Sanofi's dual-action biotech asthma drug performs well in test Positive results for Sanofi/Regeneron's dupilumab in asthma |
View full post on asthma – Google News
 Investorplace.com |
UPDATE 1-Regeneron, Sanofi asthma drug seen as potential game changer
Reuters May 21 (Reuters) – A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease … New Asthma Drug Generates Excitement For Patients — And Its Maker Antibody Gets High Marks for Asthma Control – MedPage Today Monoclonal Antibody Dupilumab Safe And Effective In Asthma Phase IIa Trial |
View full post on asthma – Google News
|
Regeneron, Sanofi asthma drug seen as potential game changer
Reuters (Reuters) – A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers … Monoclonal antibody appears effective and safe in asthma Phase IIa trial Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of … |
View full post on asthma – Google News
|
Glaxo Executives Cited in Case Now Lead Sanofi
Businessweek Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies. |
View full post on asthma – Google News
 GPB |
Glaxo Executives Cited in Case Now Lead Sanofi, Actelion
Businessweek Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies. Glaxo Settlement Pulls Back Curtain On Drug Marketing |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News